about
Common genetic variation and the control of HIV-1 in humansCan linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-scoreThe potential of antimicrobials to induce thrombocytopenia in critically ill patients: data from a randomized controlled trialImmuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in EuropeLong-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical PracticeOutcomes of influenza A(H1N1)pdm09 virus infection: results from two international cohort studiesSequence analysis of in vivo defective interfering-like RNA of influenza A H1N1 pandemic virusLiver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study CohortResponse to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation CohortAccess and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA.Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice.Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting.Plasma HIV-1 tropism and risk of short-term clinical progression to AIDS or death.Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replicationThe effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort studyThe association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies.Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational studyResumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trialLow-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing.Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study.Timing of antiretroviral therapy initiation after a first AIDS-defining event: temporal changes in clinical attitudes in the ICONA cohort.Invasive Candida infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem, and cefuroxime.Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy.Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trial.Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus.Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 yearsRelevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy.During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQPlasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or DeathRefining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patientsMultiple viral infections.Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized TherapyLong-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study.The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study.Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis.Evolution of the prevalence of HCV infection and HCV genotype distribution in HIV-infected patients in Italy between 1997 and 2015.Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression.Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts.
P50
Q21092450-39815DF3-66C4-4D60-AC79-F24267C709D7Q28477987-ED3EBB25-4A93-48A9-AB19-EE11EBF5E81BQ28535471-5C377AC6-5F88-45FF-80F3-E3573A95BAB4Q28539369-75B1A412-E114-43F4-BCC0-B44BBCEC5645Q28554567-B7622B34-521B-4315-BF98-FF907EED04AFQ30364474-C2BCBBDB-A044-4E2F-8B33-4EBAE0877C31Q30430587-AD2829E8-D057-4D1E-BA85-012C3BD66BD7Q30843946-3BED721A-1DDC-4B8B-ABAC-C8A3861F5C05Q30869874-F9E3C626-7029-4989-9AF9-91030391A42BQ31110946-6F0E89E5-ECA0-445F-981C-1ECC7CB61817Q33699364-C2196399-077A-4F9F-9303-4152B1236D53Q33982469-FF7462EB-7D48-4AC4-861D-162E3F6BFA5DQ34475217-212FB125-00F0-483F-A1B6-4FD8729CE9FEQ34476785-DE8CE3B9-16DE-4A02-94BB-891D5C264C82Q34477207-7626F94F-CB5F-473C-BA50-B85348601E63Q34477315-28EE7B5F-4C13-409B-B02D-34C3C6EE131EQ34609382-4C27BF53-3931-42E3-9653-3ACAA6F87A26Q34611788-8B5798C2-C633-4204-B95B-6A08263303D0Q34903835-2F03BD24-15A4-4A03-9091-D5E22BD1FFA7Q35006056-8C7D89BD-9F1B-41B2-8462-18C15077F5D5Q35056873-E0241F12-C7B9-45CA-94D7-3395FFC86D7AQ35093047-67103450-B8EB-45B1-BF64-F4DC5FD9AE13Q35108221-2BA06ED0-25DC-4FB4-AEE2-D12EEF6F56DAQ35507702-79B8D76E-CF01-4D56-BA43-5F46183ECFFBQ35560802-C2C6197B-E37F-4810-BFFC-D26CEB3315F6Q35629714-11CA8B75-A05B-4348-9DB9-A4527FE3098EQ35861988-880CCBE5-1139-4D64-8298-D1C54DD944A5Q35870814-FD49538D-5188-4B6E-880F-FAD418BD94C3Q36015621-111A15D9-6735-494E-AE4F-6FD7F2C2256CQ36106294-D5C29C09-227D-4FB2-A4F4-19A378A42F19Q36262454-C2F9EDFB-A517-45B1-BD20-6123FC3C7EBDQ36278470-69B4A5B5-FB9E-4857-A76E-78A6C8917D25Q36341043-A66AE10C-1B4E-472C-87C3-B6B10C329FD4Q36628396-143C7ABD-2B20-4F52-9A81-C8A352E87BF1Q37328870-71D1A17F-D14E-4780-A470-5B546B977146Q37355492-1D07C4FB-902D-4C70-B52B-C402478356AFQ37531320-A6C4CE9E-3A0C-4D31-AC25-2934A34BE08EQ38399476-BC9A760C-F61C-4D45-9B3B-4A8A57DB1D90Q38417834-FE4C6422-C71B-4067-9064-32992CECE9D3Q38434651-7D7CA91C-AFCB-4C58-A294-85233A3117DE
P50
name
Alessandro Cozzi-Lepri
@ast
Alessandro Cozzi-Lepri
@en
Alessandro Cozzi-Lepri
@es
Alessandro Cozzi-Lepri
@nl
type
label
Alessandro Cozzi-Lepri
@ast
Alessandro Cozzi-Lepri
@en
Alessandro Cozzi-Lepri
@es
Alessandro Cozzi-Lepri
@nl
prefLabel
Alessandro Cozzi-Lepri
@ast
Alessandro Cozzi-Lepri
@en
Alessandro Cozzi-Lepri
@es
Alessandro Cozzi-Lepri
@nl